Efficacy of prophylactic mastectomy in women with unilateral breast cancer: A cancer research network project

被引:214
作者
Herrinton, LJ
Barlow, WE
Yu, OC
Geiger, AM
Elmore, JG
Barton, MB
Harris, EL
Rolnick, S
Pardee, R
Husson, G
Macedo, A
Fletcher, SW
机构
[1] Kaiser Permanente, Div Res, Canc Res Network, Oakland, CA 94612 USA
[2] Kaiser Permanente, Pasadena, CA USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98195 USA
[4] Univ Washington, Sch Med, Seattle, WA 98195 USA
[5] Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA
[6] Harvard Univ, Pilgrim Hlth Care, Boston, MA 02115 USA
[7] Harvard Univ, Sch Med, Boston, MA 02115 USA
[8] Kaiser Permanente Ctr Hlth Res, Portland, OR USA
[9] HealthPartners, Minneapolis, MN USA
关键词
D O I
10.1200/JCO.2005.10.080
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose We investigated the efficacy of contralateral prophylactic mastectomy (CPM) in reducing contralateral breast cancer incidence and breast cancer mortality among women who have already been diagnosed with breast cancer. Methods This retrospective cohort study comprised approximately 50,000 women who were diagnosed with unilateral breast cancer during 1979 to 1999. Using computerized data confirmed by chart review, we identified 1,072 women (1.9%) who had CPM. We obtained covariate information for these women and for a sample of 317 women who did not undergo CPM. Results The median time from initial breast cancer diagnosis to the end of follow-up was 5.7 years. Contralateral breast cancer developed in 0.5% of women with CPM, metastatic disease developed in 10.5%, and subsequent breast cancer developed in 12.4%; 8.1% died from breast cancer. Contralateral breast cancer developed in 2.7% of women without CPM, and 11.7% died of breast cancer. After adjustment for initial breast cancer characteristics, treatment, and breast cancer risk factors, the hazard ratio (HR) for the occurrence of contralateral breast cancer after CPM was 0.03 (95% CI, 0.006 to 0.13). After adjustment for breast cancer characteristics and treatment, the HRs for the relationship of CPM with death from breast cancer, with death from other causes, and with all-cause mortality were 0.57 (95% Cl, 0.45 to 0.72), 0.78 (95% Cl, 0.57 to 1.06), and 0.60 (95% Cl, 0.50 to 0.72), respectively. Conclusion CPM seems to protect against the development of contralateral breast cancer, and although women who underwent CPM had relatively low all-cause mortality, CPM also was associated with decreased breast cancer mortality. (c) 2005 by American Society of Clinical Oncology.
引用
收藏
页码:4275 / 4286
页数:12
相关论文
共 15 条
[1]   ROBUST VARIANCE-ESTIMATION FOR THE CASE-COHORT DESIGN [J].
BARLOW, WE .
BIOMETRICS, 1994, 50 (04) :1064-1072
[2]   Analysis of case-cohort designs [J].
Barlow, WE ;
Ichikawa, L ;
Rosner, D ;
Izumi, S .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1999, 52 (12) :1165-1172
[3]   THE WOMAN AT INCREASED RISK FOR BREAST-CANCER - EVALUATION AND MANAGEMENT STRATEGIES [J].
BILIMORIA, MM ;
MORROW, M .
CA-A CANCER JOURNAL FOR CLINICIANS, 1995, 45 (05) :263-278
[4]   Completeness of information on adjuvant therapies for colorectal cancer in population-based cancer registries [J].
Cress, RD ;
Zaslavsky, AM ;
West, DW ;
Wolf, RE ;
Felter, MC ;
Ayanian, JZ .
MEDICAL CARE, 2003, 41 (09) :1006-1012
[5]   Cancer statistics, 2000 [J].
Greenlee, RT ;
Murray, T ;
Bolden, S ;
Wingo, PA .
CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) :7-33
[6]  
Hart P.M., 2001, Handbook of industrial, work and organizational psychology, V2, P93
[7]  
Hartmann L.C., 1999, NEW ENGL J MED, V340, P77, DOI DOI 10.1056/NEJM199901143400201
[8]   Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer [J].
McDonnell, SK ;
Schaid, DJ ;
Myers, JL ;
Grant, CS ;
Donohue, JH ;
Woods, JE ;
Frost, MH ;
Johnson, JL ;
Sitta, DL ;
Slezak, JM ;
Crotty, TB ;
Jenkins, RB ;
Sellers, TA ;
Hartmann, LC .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (19) :3938-3943
[9]   Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. [J].
Meijers-Heijboer, H ;
van Geel, B ;
van Putten, WLJ ;
Henzen-Logmans, SC ;
Seynaeve, C ;
Menke-Pluymers, MBE ;
Bartels, CCM ;
Verhoog, LC ;
van den Ouweland, AMW ;
Niermeijer, MF ;
Brekelmans, CTM ;
Klijn, JGM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (03) :159-164
[10]  
National Cancer Institute, SURV EP END RES SEER